Anbio Biotechnology (Class A) (NNNN) exhibits 87.2% gross margins and 17.0% return on invested capital within Health Care (Biotechnology: In Vitro & In Vivo Diagnostic Substances), balanced against a 91.5x enterprise multiple and 4.8% implied options volatility.
Sustained 87.2% gross profitability converts into 66.7% operating margin and 17.0% ROIC, outpacing sector cost of capital.
ROIC: 17.0% // GM: 87.2%YoY revenue trajectory of +5.6% paired with -1.26% free cash flow yield supports self-funded R&D and capital return.
REV YOY: +5.6% // FCF YLD: -1.26%Altman Z-Score of 3.80 and Piotroski F-Score of 5/9 indicate low near-term refinancing stress.
ALTMAN Z: 3.80 // F-SCORE: 5/9Trading at 83.6x trailing P/E (77.7x Fwd P/E) leaves valuation vulnerable if real 10Y TIPS yields spike.
P/E: 83.6x // EV/EBITDA: 91.5xOptions market prices a ±5.2% implied move with a 0.85 put/call ratio around $3.72 max pain.
IMPL MOVE: ±5.2% // P/C: 0.85Elevated industry capital intensity and customer concentration in Biotechnology: In Vitro & In Vivo Diagnostic Substances require continuous execution to defend 68.0% net margins.
NET MARGIN: 68.0% // D/E: 0.45x| FILER | SIDE | $ VALUE |
|---|---|---|
| INSPECT FULL OWNERSHIP LEDGER IN OWN <GO> | ||
| STRIKE / EXP | TYPE | PREMIUM |
|---|---|---|
| INSPECT GEX & CHAIN IN OPT <GO> | ||
Unblur the exact $50,000 delta-adjusted ETF/options hedge ratio for NNNN & activate live FRED threshold breach alerts.